Ca-EDTA restores the activity of ceftazidime- avibactam or aztreonam against carbapenemase- producing Klebsiella pneumoniae infections

被引：10

作者：

Leshan, Dhammika ^{[1
,2
,3
,4
,5
,6
]}

Shein, Aye Mya Sithu ^{[2
,3
]}

Hurst, Cameron ^{[7
]}

Monk, Peter N. ^{[8
]}

Hongsing, Parichart ^{[9
,10
]}

Phattharapornjaroen, Phatthranit ^{[11
,12
]}

Ditcham, William Graham Fox ^{[4
]}

Ounjai, Puey ^{[13
]}

Saethang, Thammakorn ^{[14
]}

Chantaravisoot, Naphat ^{[15
,16
]}

Wapeesittipan, Pattama ^{[17
]}

Luk-in, Sirirat ^{[18
]}

Sae-Joo, Sasipen ^{[2
,3
]}

Nilgate, Sumanee ^{[2
,3
]}

Rirerm, Ubolrat ^{[2
,3
]}

Tanasatitchai, Chanikan ^{[2
,3
]}

Kueakulpattana, Naris ^{[2
,3
]}

Laowansiri, Matchima ^{[2
,3
]}

Liao, Tingting ^{[19
,20
]}

Kupwiwat, Rosalyn ^{[6
,21
]}

Rojanathanes, Rojrit ^{[22
]}

Ngamwongsatit, Natharin ^{[23
]}

Tungsanga, Somkanya ^{[24
,25
]}

Leelahavanichkul, Asada ^{[2
,26
]}

Ragupathi, Naveen Kumar Devanga ^{[6
,27
,28
]}

Badavath, Vishnu Nayak ^{[29
]}

Hosseini, S. M. Ali

Kanjanabuch, Talerngsak ^{[24
,32
,33
,34
]}

Hirankarn, Nattiya ^{[2
,31
]}

Storer, Robin James ^{[35
]}

Cui, Longzhu ^{[36
]}

Amarasiri, Mohan ^{[37
]}

Ishikawa, Hitoshi ^{[38
]}

Higgins, Paul G. ^{[39
,40
,41
,42
,43
]}

Stick, Stephen M. ^{[30
,31
,44
,45
,46
]}

Kicic, Anthony ^{[44
,45
,46
,47
]}

Chatsuwan, Tanittha ^{[2
,3
]}

Abe, Shuichi ^{[5
,6
]}

机构：

[1] Yamagata Prefectural Cent Hosp, Dept Infect Dis & Infect Control, Yamagata, Japan

[2] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Fac Med, Dept Microbiol,Thai Red Cross Soc, Bangkok, Thailand

[3] Chulalongkorn Univ, Fac Med, Ctr Excellence Antimicrobial Resistance & Stewards, Bangkok, Thailand

[4] Univ Western Australia, Sch Med, Fac Hlth & Med Sci, Nedlands, WA, Australia

[5] Univ Sheffield, Biofilms & Antimicrobial Resistance Consortium ODA, Sheffield, England

[6] Yamagata Prefectural Cent Hosp, Dept Infect Dis & Infect Control, Pathogen Hunters Res Team, Yamagata, Japan

[7] Charles Darwin Univ, Molly Wardaguga Res Ctr, Brisbane, Qld, Australia

[8] Univ Sheffield, Med Sch, Dept Infect Immun & Cardiovasc Dis, Sheffield, England

[9] Mae Fah Luang Univ, Chiang Rai, Thailand

[10] Mae Fah Luang Univ, Sch Integrat Med, Chiang Rai, Thailand

[11] Mahidol Univ, Fac Med, Ctr Excellence, Dept Emergency Med,Ramathibodi Hosp, Bangkok, Thailand

[12] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg, S-40530 Gothenburg, Sweden

[13] Mahidol Univ, Fac Sci, Dept Biol, Bangkok, Thailand

[14] Kasetsart Univ, Fac Sci, Dept Comp Sci, Bangkok, Thailand

[15] Chulalongkorn Univ, Fac Med, Ctr Excellence Syst Biol, Res Affairs, Bangkok, Thailand

[16] Chulalongkorn Univ, Fac Med, Dept Biochem, Bangkok, Thailand

[17] Univ Bergen, Dept Clin Sci, Bergen, Norway

[18] Mahidol Univ, Fac Med Technol, Dept Clin Microbiol & Appl Technol, Bangkok, Thailand

[19] Chulalongkorn Univ, Fac Med, Dept Physiol, Bangkok, Thailand

[20] Chulalongkorn Univ, Fac Med, Ctr Excellence Microcirculat, Bangkok, Thailand

[21] Mahidol Univ, Fac Med, Dept Dermatol, Siriraj Hosp, Bangkok, Thailand

[22] Chulalongkorn Univ, Fac Sci, Ctr Excellence Mat & Biointerfaces, Bangkok, Thailand

[23] Mahidol Univ, Fac Vet Sci, Dept Clin Sci & Publ Hlth, Nakhon Pathom, Thailand

[24] Chulalongkorn Univ, Fac Med, Dept Med, Div Nephrol, Bangkok, Thailand

[25] Chulalongkorn Univ, Div Gen Internal Med Nephrol, Dept Med, Fac Med, Bangkok, Thailand

[26] Chulalongkorn Univ, Dept Microbiol, Translat Res Inflammat & Immunol Res Unit TRIRU, Bangkok, Thailand

[27] Univ Sheffield, Dept Chem & Biol Engn, Sheffield, England

[28] Christian Med Coll & Hosp, Dept Clin Microbiol, Vellore, India

[29] SVKMs Narsee Monjee Inst Management Studies NMIMS, Sch Pharm & Technol Management, Hyderabad 509301, India

[30] Univ Otago, Dept Microbiol & Immunol, Dunedin 9010, Otago, New Zealand

[31] Chulalongkorn Univ, Ctr Excellence Immunol & Immune Mediated Dis, Bangkok 10330, Thailand

[32] Chulalongkorn Univ, Fac Med, Ctr Excellence Kidney Metab Disorders, Bangkok, Thailand

[33] Chulalongkorn Univ, Fac Med, Sch Global Hlth, Dialysis Policy & Practice Program DiP3, Bangkok, Thailand

[34] King Chulalongkorn Mem Hosp, Peritoneal Dialysis Excellence Ctr, Bangkok, Thailand

[35] Chulalongkorn Univ, Fac Med, Off Res Affairs, Bangkok, Thailand

[36] Jichi Med Univ, Div Bacteriol, Sch Med, Tochigi, Japan

[37] Kitasato Univ, Sch Allied Hlth Sci, Dept Hlth Sci, Lab Environm Hyg, Sagamihara Minami, Kanagawa 2520373, Japan

[38] Yamagata Prefectural Univ Hlth Sci, Kamiyanagi, Yamagata 9902212, Japan

[39] Univ Cologne, Inst Med Microbiol Immunol & Hyg, Fac Med, Cologne, Germany

[40] Univ Cologne, Univ Hosp Cologne, Cologne, Germany

[41] German Ctr Infect Res, Partner Site Bonn Cologne, Cologne, Germany

[42] Univ Cologne, Fac Med, Ctr Mol Med Cologne, D-50935 Cologne, Germany

[43] Univ Cologne, Univ Hosp Cologne, D-50935 Cologne, Germany

[44] Univ Western Australia, Telethon Kids Inst, Nedlands, WA 6009, Australia

[45] Univ Western Australia, Ctr Cell Therapy & Regenerat Med, Med Sch, Nedlands, WA 6009, Australia

[46] Perth Childrens Hosp, Dept Resp & Sleep Med, Nedlands, WA 6009, Australia

[47] Curtin Univ, Sch Publ Hlth, Bentley, WA 6102, Australia

来源：

ISCIENCE | 2023年 / 26卷 / 07期

关键词：

PSEUDOMONAS-AERUGINOSA; COLISTIN-RESISTANT; ANTIBIOTIC-RESISTANCE; BIOFILM FORMATION; BETA-LACTAMASE; CALCIUM-EDTA; COMBINATION; EFFICACIES; INHIBITOR; MODEL;

D O I：

10.1016/j.isci.2023.107215

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Developing an effective therapy to overcome carbapenemase-positive Klebsiella pneumoniae (CPKp) is an important therapeutic challenge that must be ad-dressed urgently. Here, we explored a Ca-EDTA combination with aztreonam or ceftazidime-avibactam in vitro and in vivo against diverse CPKp clinical iso-lates. The synergy testing of this study demonstrated that novel aztreonam-Ca-EDTA or ceftazidime-avibactam-Ca-EDTA combination was significantly effective in eliminating planktonic and mature biofilms in vitro, as well as eradicating CPKp infections in vivo. Both combinations revealed significant therapeutic efficacies in reducing bacterial load in internal organs and protecting treated mice from mor-tality. Conclusively, this is the first in vitro and in vivo study to demonstrate that novel aztreonam-Ca-EDTA or ceftazidime-avibactam-Ca-EDTA combinations pro-vide favorable efficacy and safety for successful eradication of carbapenemase-producing Klebsiella pneumoniae planktonic and biofilm infections.

引用

页数：24

共 50 条

[41] Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae Ceftazidime-avibactam against CR- KP infections
Gu, Jie
Xu, Jie
Zuo, Ting-ting
Chen, Yan-bin
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 26 : 20 - 25
[42] Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive Klebsiella pneumoniae MBL plus , NDM plus [Response to Letter]
Szymanski, Mateusz
Skiba, Malgorzata M.
Piasecka, Malgorzata
INFECTION AND DRUG RESISTANCE, 2024, 17 : 3159 - 3160
[43] In vitro activity of ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae in Greece: A single-centre study
Protonotariou, Efthymia
Meletis, Georgios
Kachrimanidou, Melania
Papadopoulou, Dimitra
Stamou, Aikaterini
Arhonti, Maria
Skoura, Lemonia
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 20 : 82 - 83
[44] Clinical and Microbiological characteristics of patients with ceftazidime/avibactam-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains
Szu-Yu Liu
Sheng-Hua Chou
Chien Chuang
Chih-Han Juan
Yu-Chien Ho
Hsiang-Ling Ho
Liang Chen
Yi-Tsung Lin
Annals of Clinical Microbiology and Antimicrobials, 24 (1)
[45] Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline
Guedes, Mariana
Duro, Raquel
Fonseca, Telma
Abreu, Isabel
Rocha-Pereira, Nuno
IDCASES, 2020, 20
[46] Correction to: Epidemiology and in vitro activity of ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates
Sofia Maraki
Viktoria Eirini Mavromanolaki
Eleni Magkafouraki
Panagiotis Moraitis
Dimitra Stafylaki
Anna Kasimati
Effie Scoulica
Infection, 2022, 50 : 1639 - 1639
[47] In Vitro Efficacy of Ceftazidime-avibactam Against blaOXA-48-producing Klebsiella pneumoniae Isolates
Cag, Yasemin
Kocoglu, Muecahide Esra
Caskurlu, Hulya
Haciseyitoglu, Demet
Mirza, Hasan Cenk
Guclu, Aylin Uskudar
Cetinkaya, Riza Aytac
Vahaboglu, Haluk
MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2023, 12
[48] In Vitro Activity of Ceftolozane/tazobactam and Ceftazidime/avibactam Against Carbapenemase-producing Pseudomonas aeruginosa
Aydemir, Ozlem
Terzi, Huseyin Agah
Koroglu, Mehmet
Altindis, Mustafa
MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2019, 8
[49] Use of ceftazidime-avibactam in a preterm infant with urinary tract infection with bacteremia caused by carbapenemase-producing Klebsiella pneumoniae
Pantoja, Miguel angel
Delpiano, Luis
Arriagada, Tamara
REVISTA CHILENA DE INFECTOLOGIA, 2023, 40 (05): : 559 - 563
[50] Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient
Gaibani, Paolo
Gatti, Milo
Rinaldi, Matteo
Pesce, Cristina Crovara
Lazzarotto, Tiziana
Giannella, Maddalena
Lombardo, Donatella
Amadesi, Stefano
Viale, Pierluigi
Pea, Federico
Ambretti, Simone
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 113 : 213 - 217

← 1 2 3 4 5 →